BioCardia Inc (BCDA) Stock Analysis

AI analysis of BioCardia Inc (BCDA)

Hold

BioCardia Inc (BCDA) is currently a hold. The stock is trading at $0.8698, which is significantly below its 52-week high of $1.80, indicating potential upside. However, the RSI is at 31.606, suggesting the stock is oversold, but this could also indicate a continued downtrend. The forward P/E ratio is currently 0, reflecting a lack of earnings expectations, which is concerning for long-term investors. The company has reported a net loss of $2,259,000 in Q1 2026, and while there is FDA confirmation for its heart failure trial, the financials remain weak with a gross margin of 0% in recent quarters. The primary risk is the company's ongoing losses and lack of revenue generation, with a net margin of -13,700% in Q4 2024, which could hinder recovery efforts and investor confidence.

Valuation Metrics

The current forward P/E ratio for BioCardia Inc (BCDA) is 0.00, compared to its 5-year average forward P/E of -2.65.

Forward P/E

Overvalued

5Y Average P/E

-2.65

Current P/E

0.00

Overvalued

-0.07

Undervalued

-5.23

Forward EV/EBITDA

Overvalued

5Y Average EV/EBITDA

-1.18

Current EV/EBITDA

0.00

Overvalued

-0.41

Undervalued

-1.96

Forward P/S

Fair

5Y Average P/S

78.75

Current P/S

0.00

Overvalued

219.93

Undervalued

-62.43

BCDA FAQ — answered by Alphio AI

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

BioCardia Inc (BCDA) is currently a hold. The stock is trading at $0.8698, which is significantly below its 52-week high of $1.80, indicating potential upside. However, the RSI is at 31.606, suggesting the stock is oversold, but this could also indicate a continued downtrend. The forward P/E ratio is currently 0, reflecting a lack of earnings expectations, which is concerning for long-term investors. The company has reported a net loss of $2,259,000 in Q1 2026, and while there is FDA confirmation for its heart failure trial, the financials remain weak with a gross margin of 0% in recent quarters. The primary risk is the company's ongoing losses and lack of revenue generation, with a net margin of -13,700% in Q4 2024, which could hinder recovery efforts and investor confidence.